Chris Schott is ranked #1348 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

JPM

Chris Schott

Q: How accurate are Chris Schott's stock ratings?

About 62% of Chris's ratings were profitable over a one-year hold, with an average return of +4.8% per rating, measured by 13Foresight from historical prices.

J.P. Morgan

Wall Street Analyst

★★★☆☆

#1348

on 13Foresight · ranked by our own returns

62%

Success Rate

+4.8%

Average Return

39 of 63 calls profitable · +23.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 62% of Chris Schott's ratings turned a profit when each position was held for 1 year — averaging +4.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

73 Buy 35 Hold 3 Sell

Chris's Stock Coverage 27 ratings · 2026-09-28

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
PFE Pfizer	Sep 25, 2026	HOLD	Buy +17.2% avg upside 45 analysts	$28.00 2.35% Downside	-0.5%	·
ABBV AbbVie	Sep 25, 2026	BUY	Strong Buy -7.9% avg upside 47 analysts	$285.00 7.91% Upside	+0.7%	·
REGN Regeneron	Sep 25, 2026	BUY	Strong Buy +0.3% avg upside 59 analysts	$900.00 14.27% Upside	+0.0%	·
JNJ Johnson & Johnson	Sep 25, 2026	HOLD	Strong Buy -8.9% avg upside 40 analysts	$270.00 0.37% Downside	+0.0%	·
IL:TEVA Teva	Sep 24, 2026	BUY	Strong Buy +7.5% avg upside 3 analysts	—	·	·
AMRX Amneal Pharmaceuticals	Sep 21, 2026	BUY	Buy -6.4% avg upside 19 analysts	—	-1.9%	·
LLY Eli Lilly & Co	Sep 02, 2026	BUY	Strong Buy -8.9% avg upside 49 analysts	$1400.00 18.23% Upside	+2.0%	·
MRK Merck & Company	Aug 19, 2026	BUY	Strong Buy -4.9% avg upside 43 analysts	—	-2.0%	·
ELAN Elanco Animal Health	Aug 11, 2026	BUY	Strong Buy +40.4% avg upside 18 analysts	—	-1.2%	·
ZTS Zoetis	Aug 10, 2026	BUY	Buy +70.7% avg upside 23 analysts	$115.00 61.77% Upside	-4.5%	·
RPRX Royalty Pharma	Aug 10, 2026	BUY	Strong Buy +1.1% avg upside 15 analysts	$62.00 6.56% Upside	+1.1%	·
VTRS Viatris	Aug 10, 2026	HOLD	Buy +29.9% avg upside 22 analysts	$18.00 0.95% Upside	+10.3%	·
AMGN Amgen	Aug 06, 2026	HOLD	Buy -22.6% avg upside 57 analysts	$350.00 15.51% Downside	+3.0%	·
GILD Gilead Sciences	Aug 06, 2026	BUY	Strong Buy -21.6% avg upside 66 analysts	$160.00 6.01% Upside	+17.0%	·
BMY Bristol-Myers Squibb	Aug 04, 2026	BUY	Buy -2.3% avg upside 42 analysts	$73.00 16.07% Upside	-4.6%	·
BIIB Biogen	Jul 30, 2026	HOLD	Strong Buy +12.1% avg upside 53 analysts	$210.00 7.79% Downside	+9.5%	·
PRGO Perrigo Company	Feb 27, 2026	HOLD	Buy +344.6% avg upside 20 analysts	$15.00 2.69% Downside	+24.9%	·
OGN Organon	Feb 13, 2026	SELL	Sell +8.2% avg upside 9 analysts	$11.00 19.84% Downside	-86.1%	·
IDXX Idexx Laboratories	Nov 03, 2025	BUY	Buy +39.2% avg upside 17 analysts	$775.00 49.30% Upside	-29.0%	·
CHRS Coherus Biosciences	May 25, 2023	HOLD	Buy +994.9% avg upside 18 analysts	$8.00 608.04% Upside	-55.5%	·
TSE:BHC Bausch Health Companies	Jul 28, 2022	HOLD	Buy +630.6% avg upside 29 analysts	—	+130.2%	·
TXMD TherapeuticsMD	May 19, 2020	HOLD	Buy +204.9% avg upside 8 analysts	—	·	·
DE:MRK Merck KGaA	Mar 09, 2020	BUY	Buy +2.5% avg upside 34 analysts	$86.15 36.27% Downside	+34.2%	·
PCRX Pacira Pharmaceuticals	Feb 20, 2020	HOLD	Buy +52.5% avg upside 22 analysts	$54.00 114.94% Upside	+51.7%	·
SNNAQ Sienna Biopharmaceuticals	May 13, 2019	HOLD	Buy +299999900.1% avg upside 2 analysts	—	·	·
KALA KALA BIO	Nov 17, 2017	BUY	Strong Buy +44715.6% avg upside 9 analysts	$35.00 7259.19% Upside	·	·
AMRN Amarin	Oct 17, 2013	HOLD	Hold -34.6% avg upside 18 analysts	—	-47.8%	·

🔒 22 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Chris Schott — Frequently Asked Questions

How accurate are Chris Schott's stock ratings?

Based on the calls 13Foresight could measure, about 62% of Chris's ratings were profitable over a one-year hold, with an average return of +4.8% per rating, or +23.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Chris ranked on 13Foresight?

Chris Schott is currently ranked #1348 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Chris cover?

Chris most recently has ratings on PFE, ABBV, REGN, JNJ, IL:TEVA, AMRX, LLY, MRK, ELAN, ZTS, RPRX, VTRS and 15 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Chris Schott

Rating Distribution

Welcome to 13Foresight!